BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received its first patent related to the ability of its lead drug candidate, Thymosin beta 4 (Tß4), to treat wounds and other injuries and disorders of the eye. The Australian patent includes Tß4, analogues, fragments and other derivatives, methods of use and delivery, either independently or in combination with other agents in novel compositions. The patent expires in 2022. Similar patent applications have been submitted throughout the world.
